# Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence

> **NCT07521137** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sano Chemicals Inc** · enrollment: 36 (estimated)

## Conditions studied

- Candidiasis, Vulvovaginal

## Interventions

- **DRUG:** OCF001 Intravaginal Gel
- **DRUG:** Placebo Gel

## Key facts

- **NCT ID:** NCT07521137
- **Lead sponsor:** Sano Chemicals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-20
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07521137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07521137, "Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07521137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*